NFL Biosciences Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	2	1.91	2.34	1.05	3.04
Short-Term Investments	0.2	0.2	0.19	0.16	0.17
Cash & Short-Term Investments	2.2	2.11	2.53	1.21	3.2
Cash Growth	4.19%	-16.45%	108.29%	-62.11%	933.15%
Other Receivables	0.97	1.06	1.11	0.74	0.22
Receivables	0.97	1.06	1.11	0.74	0.22
Prepaid Expenses	0.24	0.17	0.18	0.3	0.13
Total Current Assets	3.41	3.34	3.82	2.26	3.56
Property, Plant & Equipment	0.1	0.12	0.01	0	0
Long-Term Investments	-	-	-	-	0
Other Intangible Assets	0.16	0.15	0.14	0.14	0.12
Other Long-Term Assets	-	-0	0	-	-
Total Assets	3.66	3.61	3.97	2.4	3.69
Accounts Payable	0.51	1.15	2.16	1.19	0.12
Accrued Expenses	0.24	0.25	-	0.21	-
Short-Term Debt	-	-	-	0	0
Current Income Taxes Payable	-	-	0.2	-	0.07
Total Current Liabilities	0.75	1.4	2.37	1.4	0.19
Long-Term Debt	0.43	0.04	0.06	0.08	0.09
Long-Term Leases	0.15	-	-	-	-
Other Long-Term Liabilities	2.02	1.19	1.19	0.07	0.13
Total Liabilities	3.36	2.63	3.62	1.55	0.4
Common Stock	0.38	0.29	0.24	0.16	0.16
Additional Paid-In Capital	3.24	2.76	7.27	4.11	4.11
Retained Earnings	-3.32	-2.08	-7.17	-3.42	-0.98
Comprehensive Income & Other	0	0	-	-0	-
Shareholders' Equity	0.31	0.98	0.35	0.84	3.29
Total Liabilities & Equity	3.66	3.61	3.97	2.4	3.69
Total Debt	0.58	0.04	0.06	0.08	0.09
Net Cash (Debt)	1.62	2.07	2.47	1.13	3.12
Net Cash Growth	-21.86%	-16.00%	118.12%	-63.74%	1285.36%
Net Cash Per Share	0.12	0.21	0.30	0.22	0.60
Filing Date Shares Outstanding	12.67	9.83	8.16	5.23	5.23
Total Common Shares Outstanding	12.67	9.83	8.16	5.23	5.23
Working Capital	2.65	1.94	1.45	0.86	3.37
Book Value Per Share	0.02	0.10	0.04	0.16	0.63
Tangible Book Value	0.15	0.83	0.21	0.71	3.16
Tangible Book Value Per Share	0.01	0.08	0.03	0.14	0.60
Machinery	0.18	0.18	0.05	-	-